Exagen (NASDAQ:XGN – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. Exagen had a negative return on equity of 84.26% and a negative net margin of 30.36%. The business had revenue of $12.51 million during the quarter, compared to analysts’ expectations of $13.55 million. During the same period in the prior year, the firm posted ($0.31) EPS. Exagen updated its FY 2024 guidance to EPS.
Exagen Stock Down 1.4 %
Shares of NASDAQ:XGN opened at $2.75 on Thursday. The business has a fifty day moving average of $2.84 and a 200-day moving average of $2.37. The company has a debt-to-equity ratio of 1.13, a quick ratio of 4.32 and a current ratio of 4.32. Exagen has a twelve month low of $1.30 and a twelve month high of $3.71.
Analysts Set New Price Targets
Separately, William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday.
About Exagen
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Read More
- Five stocks we like better than Exagen
- The 3 Best Blue-Chip Stocks to Buy Now
- Can United States Cellular Ride Higher on Its Spectrum Strategy?
- How to Start Investing in Real Estate
- HubSpot’s Growth in CRM: Can It Compete With Salesforce?
- How to Use the MarketBeat Stock Screener
- Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?”
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
